Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer
Open Access
- 1 September 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 9 (9), 974-984
- https://doi.org/10.1002/sctm.19-0423
Abstract
Adoptive cell therapy (ACT) is an approach to cancer treatment that involves the use of antitumor immune cells to target residual disease in patients after completion of chemo/radiotherapy. ACT has several advantages compared with other approaches in cancer immunotherapy, including the ability to specifically expand effector cells in vitro before selection for adoptive transfer, as well as the opportunity for host manipulation in order to enhance the ability of transferred cells to recognize and kill established tumors. One of the main challenges to the success of ACT in cancer clinical trials is the identification and generation of antitumor effector cells with high avidity for tumor recognition. Natural killer (NK) cells, cytokine-induced killers and natural killer T cells are key innate or innate-like effector cells in cancer immunosurveillance that act at the interface between innate and adaptive immunity, to have a greater influence over immune responses to cancer. In this review, we discuss recent studies that highlight their potential in cancer therapy and summarize clinical trials using these effector immune cells in adoptive cellular therapy for the treatment of cancer.This publication has 128 references indexed in Scilit:
- Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor RegressionClinical Cancer Research, 2011
- Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: Reversing tumor-induced defectsClinical Immunology, 2011
- Murine induced pluripotent stem cells can be derived from and differentiate into natural killer T cellsJCI Insight, 2010
- NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effectsBlood, 2010
- NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid LeukemiaJournal of Clinical Oncology, 2010
- Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptorsBlood, 2009
- 2B4 (CD244) Signaling by Recombinant Antigen-specific Chimeric Receptors Costimulates Natural Killer Cell Activation to Leukemia and Neuroblastoma CellsClinical Cancer Research, 2009
- Engineering antigen-specific primary human NK cells against HER-2 positive carcinomasProceedings of the National Academy of Sciences of the United States of America, 2008
- Diverse cytokine production by NKT cell subsets and identification of an IL-17–producing CD4 − NK1.1 − NKT cell populationProceedings of the National Academy of Sciences of the United States of America, 2008
- Peripheral blood IFN‐γ‐secreting Vα24+Vβ11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor loadInternational Journal of Cancer, 2005